clinical trial · NCT03158064
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Germ Cell TumorNonseminomatous Germ Cell TumorSeminomaGerminomatous Germ Cell TumorDysgerminomaPineal Germ Cell TumorDurvalumabTremelimumab
brief summary
The purpose of this study is to test the safety and effectiveness of durvalumab with tremelimumab in patients with relapsed or refractory germ cell tumors.
started
May 15, 2017
primary completion
Nov 1, 2026
completion
Nov 1, 2026
last updated
Sep 18, 2026
official title
A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol